Ann: CHM CORE-NK vactosertib Phase 1b study re-opens enrolment, page-8

CHM has been branded as a off the shelf stem cell biotech. Thanks to the CRLs that MSB have received from the FDA, off the shelf MSCs are a long way from being viewed positively.
This could be about to turn around as MSB has received indications from the FDA that has given them confidence to resubmit their BLA. Success for MSB will result in significant appreciation of CHM technology. A avalanche of funds will flow into off the shelf stem cell companies. Investors today will be well rewarded for taking risk. The risk comes down to how much you think the FDA has moved and when that long awaited approval will come.